FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older 1 ...
247 patients (mean age 14.3±7.6 years) were enrolled from study sites in North America, Europe, and Australia, with a median fenfluramine exposure of 364 days (range: 19–537) and a mean daily dose of ...
How Does Fintepla Work for Seizures? Seizures are caused by sudden electrical activity changes in the brain. These changes are temporary but result in changes in movement, behavior, sensation, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results